Nanobiotix SA

Voting Rights and Shares Capital of the Company

12 سبتمبر 2025 10:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

02 سبتمبر 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

26 أغسطس 2025 23:00:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

07 يوليو 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 يونيو 2025 13:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

27 مايو 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

21 مايو 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 مايو 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

11 مايو 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

04 مايو 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

29 أبريل 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 أبريل 2025 13:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

02 أبريل 2025 13:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

30 مارس 2025 23:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

27 مارس 2025 13:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

20 مارس 2025 13:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

17 مارس 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 مارس 2025 14:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

12 فبراير 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

29 يناير 2025 13:15:00 بحسب Nasdaq GlobeNewswire